Whole Genome Sequencing Aims To Shorten Rare Disease Diagnosis

Baylor Genetics is advocating for whole genome sequencing (WGS) to become the standard of care for rare disease diagnosis, aiming to significantly shorten the average five-year diagnostic journey for millions of patients. The organization believes that implementing WGS as a first-line tool will allow for earlier and more comprehensive testing, which is crucial for impacting patient care trajectories positively. Currently, WGS is recommended in professional guidelines for conditions like intellectual disability, developmental delay, congenital anomalies, and unexplained epilepsy.

Despite growing recognition and guideline recommendations, insurance coverage for WGS remains inconsistent. Internal data from Baylor Genetics in March 2026 indicates that approximately 58% of U.S. commercial payers and 73% of Medicaid programs cover WGS in outpatient settings. This variability in coverage presents a significant barrier to widespread adoption and highlights the need for systemic change.

The organization emphasizes that while scientific progress has been substantial, translating these innovations into real-world patient impact requires strengthening the connection between discovery and clinical care. Achieving a "genome-first" approach necessitates accelerating access to testing, improving clinical implementation, expanding insurance coverage, and broadening clinical guidelines. These efforts are vital to ensure that patients receive timely and accurate diagnoses, thereby improving their health outcomes and reducing the emotional and financial burden of prolonged diagnostic odysseys.